AI-driven treatment approach and growing Fragile X Syndrome market size
Healx Pharma has recently partnered with Boehringer Ingelheim to advance
the treatment market and invest in R&D related to rare neurological
disorders.
Under the deal signed, Healx Artificial Intelligence (AI) drug discovery
platform- Healnet will help in identifying the indications that can be treated
with the use of therapies and drugs from the Boehringer Ingelheim’s pipeline.
AI-powered biotechnology company, Healx has proven that its AI-driven Healnet has identified around eight drugs that can be repurposed to offer a potential and efficient cure for Rare neurological disorder...
